Literature DB >> 7617828

Changes induced by sodium cromoglycate in brain catecholamine turnover in morphine dependent and abstinent mice.

O San-Martín-Clark1, B Cuéllar, J De Alba, J C Leza, P Lorenzo.   

Abstract

The effects of sodium cromoglycate (CRO) were studied in relation to the metabolism of brain catecholamines: dopamine (DA) and noradrenaline (NA), and their metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 4-hydroxy-3-methoxyphenylethyleneglycol (MHPG). CRO was injected SC in control mice, morphine-tolerant mice (tolerance was induced by SC implantation of a 75 mg morphine pellet; CRO was administered on day 4 of addiction) and 30 min before abstinence (withdrawal was induced by SC injection of naloxone (1 mg/kg) on day 4 of addiction). Brain catecholamines and their metabolites were measured using high performance liquid chromatography coupled with electrochemical detection (HPLC-ECD), for DA, NA, DOPAC and HVA, and coupled with fluorescence detection for MHPG. The ratios of DOPAC + HVA/DA and MHPG/NA were kept as an index of DA and NA turnovers, respectively. CRO administered 30 min before naloxone-precipitated withdrawal diminished significantly NA levels in frontal cortex. CRO increased DA turnover in striatum and frontal cortex in naive animals and significantly diminished DA levels in frontal cortex and DOPAC levels in frontal cortex and midbrain in morphine-dependent mice. These findings are discussed in relation to the protective effects of CRO on opiate withdrawal and the effects of CRO on locomotor activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617828     DOI: 10.1007/BF02245965

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Role of catecholaminergic mechanisms in the expression of the morphine abstinence syndrome in rats.

Authors:  A Herz; J Bläsig; R Papeschi
Journal:  Psychopharmacologia       Date:  1974

2.  The role of dopamine and norepinephrine in the naloxone-induced abstinence of morphine-dependent mice.

Authors:  Y Maruyama; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

3.  The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine.

Authors:  P Vezina; J Stewart
Journal:  Brain Res       Date:  1989-10-09       Impact factor: 3.252

4.  Quantitation of total MHPG in the rat brain using a non enzymatic hydrolysis procedure. Effects of drugs.

Authors:  F Artigas; M J Sarrias; A Adell; E Gelpí
Journal:  Life Sci       Date:  1986-10-27       Impact factor: 5.037

5.  Brain catecholamine metabolites and behavior in morphine withdrawal.

Authors:  A C Swann; J D Elsworth; D S Charney; D M Jablons; R H Roth; D E Redmond; J W Maas
Journal:  Eur J Pharmacol       Date:  1982-12-24       Impact factor: 4.432

6.  Evidence of a preferential role of brain serotonin in the mechanisms leading to naloxone-precipitated compulsive jumping in morphine-dependent rats.

Authors:  L Cervo; C Rochat; S Romandini; R Samanin
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Acceleration of cerebral noradrenaline turnover after morphine withdrawal and its retardation by acute morphine administration in rats.

Authors:  L M Attila; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

8.  Involvement of 5-hydroxytryptamine in the analgesic action of pethidine and morphine in mice.

Authors:  R Botting; A Morinan
Journal:  Br J Pharmacol       Date:  1982-04       Impact factor: 8.739

9.  Changes induced by sodium cromoglycate on brain serotonin turnover in morphine dependent and abstinent mice.

Authors:  O San-Martin-Clark; J C Leza; I Lizasoain; P Lorenzo
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Formation and clearance of norepinephrine glycol metabolites in mouse brain.

Authors:  P P Li; J J Warsh; D D Godse
Journal:  J Neurochem       Date:  1984-11       Impact factor: 5.372

View more
  1 in total

1.  A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid β in the brain in a transgenic model of Alzheimer disease.

Authors:  Yukiko Hori; Shuko Takeda; Hansang Cho; Susanne Wegmann; Timothy M Shoup; Kazue Takahashi; Daniel Irimia; David R Elmaleh; Bradley T Hyman; Eloise Hudry
Journal:  J Biol Chem       Date:  2014-12-02       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.